Standard BioTools Inc. Gain (Loss) on Sale of Project
Standard BioTools Inc. (LAB) reported Gain (Loss) on Sale of Project of $172.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:GainLossOnSaleOfProject · last filed 2026-08-05
- Standard BioTools Inc. gain (loss) on sale of project for the quarter ending 2026-06-30 was $0.00.
- Standard BioTools Inc. gain (loss) on sale of project for the quarter ending 2026-03-31 was $172.29M.
- Standard BioTools Inc. gain (loss) on sale of project for the quarter ending 2025-06-30 was $0.00.
- Standard BioTools Inc. gain (loss) on sale of project for the quarter ending 2025-03-31 was $0.00.
| Period end | Gain (Loss) on Sale of Project 3 month | Gain (Loss) on Sale of Project 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $172.29M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $172.29M 10-Q · filed 2026-05-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |